<DOC>
	<DOC>NCT01459562</DOC>
	<brief_summary>The purpose of this study is to determine the safety, pharmacodynamic and pharmacokinetic profiles of a novel therapeutic drug when administered to healthy volunteers.</brief_summary>
	<brief_title>First in Human Study of an Anti-IFN Gamma Monoclonal Antibody in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>healthy adults between 18 and 50 years old non smokers able to adhere to study protocol requirements any abnormal clinical safety laboratory parameters</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>